CSL Logs $6.5 Billion Impairment as Shares Tumble to Decade-Low

CSL posts $6.5B impairment from Vifor acquisition, cuts fiscal 2026 profit target, and launches $500M cost-saving plan as stock hits 10-year low.

A 90-day strategic review has forced CSL to confront an uncomfortable reality: its ambitious acquisition of Vifor Pharma has failed to deliver as expected. The Australian biotech giant on Monday unveiled a staggering $6.5 billion non-cash impairment charge, slashed its full-year guidance, and watched its stock price collapse to levels not seen in nearly ten years.

Interim chief executive Gordon Naylor, who ordered the deep-dive shortly after taking the helm, detailed the damage in stark terms. The largest chunk—$5 billion—relates to the 2021 takeover of kidney specialist CSL Vifor and underutilised manufacturing capacity. The group now expects fiscal 2026 revenue of roughly $15.2 billion and adjusted net profit after tax and amortisation (NPATA) of about $3.1 billion, down from the prior target of $3.3 billion. The write-downs will be spread across the 2026 and 2027 financial years.

The profit warning reflects a convergence of headwinds across three key businesses. Weaker US immunoglobulin sales, driven by inventory normalisation, are costing the top line $300 million. A slide in Chinese albumin demand and pricing pressure has carved out a further $200 million. Geopolitical tensions in the Middle East and stepped-up competition have added another $150 million to the toll. The only bright spot: CSL’s Seqirus influenza vaccines division is performing slightly better than anticipated.

To offset the pressure, management is launching a sweeping efficiency drive aimed at delivering annual cost savings of $500 million to $550 million by fiscal 2028. The programme includes consolidating plasma collection centres and streamlining the organisational structure. Investors responded by pounding the stock more than 15% lower to around €62, wiping more than A$11 billion off the company’s market capitalisation in a single session.

The board is pressing ahead with its search for a permanent CEO. In a separate management reshuffle, Diego Sacristan will succeed Andy Schmeltz as chief commercial officer in July, with Schmeltz retiring. The next major financial update is due in August 2026 alongside the full-year results—when CSL will either prove it has bottomed out or face another round of painful surprises.